Innovative Targeting Solutions Inc. Extends Research Collaboration with Amgen
BURNABY, BC, Feb. 19, 2014 /PRNewswire/ – Innovative Targeting Solutions Inc.
(ITS), the developer of the next generation protein engineering
technology (HuTARG(TM)), today announced the extension of its research collaboration with
Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS’
HuTARG(TM) technology. Under the terms of the agreement, ITS is entitled
to specific license payments and development milestones.
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held
company that has developed a next generation platform for the
generation of fully human antibody therapeutics using its proprietary
HuTARG(TM) technology. The HuTARG(TM) technology is a fully mammalian
technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit
SOURCE Innovative Targeting Solutions Inc